BioSpace News Archive

Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2023.

Alaunos Therapeutics, Inc. today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, at the McCormick Place Convention Center in Chicago.

Agilent Technologies Inc. (NYSE: A) will release financial results and hold an earnings conference call for the second quarter of fiscal year 2023 after the stock market closes on Tuesday, May 23 at 1:30 p.m. PDT.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 2 through 5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to TRIKAFTA® based on in vitro data.

RaySearch Laboratories AB announces that the date for publication of the annual report for 2022 will be April 28.

The Galactosemia Foundation urges the U.S Food and Drug Administration (FDA) to incorporate the experiences and perspectives of people living with galactosemia and their caregivers in the agency’s review of govorestat (AT-007), the potential first-ever treatment for this rare genetic disease that can be life-threatening for newborns and cause severe lifelong complications.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced its financial results for the first quarter ended March 31, 2023, and provided an update on its clinical pipeline and other corporate developments.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 3, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023, and recent operational highlights.

Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, reported its first quarter 2023 financial results.

Accuray Incorporated reported financial results for the third quarter of fiscal 2023 ended March 31, 2023.